Full Press Release Details
Focused on Novel Clinical Trial Designs to Advance Next Generation of Alzheimer's Disease Treatments
INmune Bio, a leader in novel therapies
and innovative trial design for AD participates in 15th CTAD conference in San Francisco November 29th to
Boca Raton, Florida, Nov. 29, 2022 (GLOBE NEWSWIRE) -- INmune Bio,
Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology company focused on developing treatments that harness
the patient's innate immune system to fight disease will participate in the 15th CTAD Conference in San Francisco
November 29th to December 2nd.
"This year's CTAD is showcasing a potential approvable
therapy for the treatment of Alzheimer's Disease (AD) that targets amyloid," said RJ Tesi MD, CEO of INmune. "While
anti-amyloid therapies may slow the rate of cognitive decline, we believe the goal for AD therapy should be to stop progression of the
disease. This will require the incorporation of novel biomarkers into innovative clinical trial designs."
INMB continues an ongoing AD Phase 2 program focused on stopping the
progression of AD by focusing on four unique elements, including: (i) enrichment criteria; (ii) novel, non-invasive neuroimaging biomarkers;
(iii) use of EMACC as a cognitive endpoint; and (iv) strategic trial design. The following describes these four unique elements:
"The use of novel enrolment criteria, easily measured pharmacodynamic
end-points, innovative trial design and cognitive testing strategies are needed to progress the AD field beyond traditional anti-amyloid
therapies," said CJ Barnum, VP CNS Drug Development. "We believe the use of non-invasive neuroimaging biomarkers and fit-for-purpose
cognitive end-points will help develop effective therapies for AD and other forms of dementia. If the field continues to focus on the
failed development strategies used for the last 20 years, little progress will be made. Our strategy is different, and it is our belief
that it will ultimately be better."
About XPro (XPro1595 )
XPro is a next-generation inhibitor of tumor necrosis factor
(TNF) that is currently in clinical trial and acts differently than currently available TNF inhibitors in that it neutralizes soluble
TNF (sTNF), without affecting trans-membrane TNF (tmTNF) or TNF receptors. XPro could have potential substantial beneficial effects
in patients with neurologic disease by decreasing neuroinflammation, improving axonal quality and synaptic function while promoting remyelination.
About INmune Bio, Inc.
INmune Bio, Inc. is a publicly traded
(NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease.
INmune Bio has two product platforms that are both in clinical trials: The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform
utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic
driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03 ), Mild Alzheimer's
disease, Mild Cognitive Impairment and treatment-resistant depression (XPro ). The Natural Killer Cell Priming Platform includes
INKmune developed to prime a patient's NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio's
product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic and solid tumor malignancies,
and chronic inflammation. To learn more, please visit www.inmunebio.com.
Forward Looking Statements
Clinical trials are in early stages and there is no assurance that
any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute
forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statements contained
in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private
Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject
to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those
described by the forward-looking statements as a result of these risks and uncertainties. INB03 , XPro1595, and INKmune are
still in clinical trials or preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA)
or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific
results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but
are not limited to, risks and uncertainties relating to the Company's ability to produce more drug for clinical trials; the availability
of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies
and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing
and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings
with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K, the Company's Quarterly Reports
on Form 10-Q and the Company's Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements
in order to reflect any event or circumstance that may arise after the date of this release.
(516) 842-9614 x-823